ストックスクリーナーアプリを入手
22.76
1.39%
-0.32
Immunome Inc (IMNM) 最新ニュース
IMNM|Immunome Inc|Price:22.590|Chg%:+0.380 - TradingKey
Immunome CTO Philip Tsai Awarded 38,250 RSUs and 76,500 Stock Options in July 2026 Equity Grant - Kalkine Media
Immunome Grants Chief Business Officer Kinney Over $1.3 Million in Stock Options and RSUs - Kalkine Media
Immunome Inc (IMNM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Immunome Inc (IMNM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Immunome Inc (IMNM) Institutional Confidence - TradingKey
Immunome Inc (IMNM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Immunome, Inc. Revenue Breakdown – BOATS:IMNM - TradingView
IMNM|Immunome Inc|Price:22.220|Chg%:+0.210 - TradingKey
TradingKey - TradingKey
Immunome Inc. (IMNM) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Immunome Inc (IMNM) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Immunome, Inc. (IMNM) stock price, news, quote and history - Yahoo Finance Australia
LifeSci Capital Maintains Immunome(IMNM.US) With Buy Rating, Maintains Target Price $40 - Moomoo
IMNM Reiterates by Wedbush -- Price Target Maintained at $31 - GuruFocus
Immunome doses first patient in IM-3050 trial - grafa.com
Immunome doses first patient in IM-3050 cancer therapy trial By Investing.com - Investing.com South Africa
Immunome (IMNM) Begins Phase 1 Trial for IM-3050 in Advanced Sol - GuruFocus
Immunome doses first patient in IM-3050 cancer therapy trial - Investing.com
Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-3050, an FAP-Targeted Radioligand Therapy, in Patients with FAP-Expressing Advanced Solid Tumors - Business Wire
Price-Driven Insight from (IMNM) for Rule-Based Strategy - Stock Traders Daily
Immunome (IMNM) NDA Acceptance Puts Valuation Back In Focus - Sahm
Why Immunome (IMNM) Is Down 8.2% After FDA Accepts Varegacestat NDA With Strong Phase 3 Data - webull.com
Immunome stock up 32% in a month: Here's what you should know - MSN
What Do Recent Insider Sales at Immunome (IMNM) Signal - Kavout | AI
Immunome granted FDA review for tumor candidate - msn.com
Immunome Inc. (IMNM) Q1 2026 Earnings: EPS Beat Highlights Cost Discipline Amid Pre-Revenue Stage - dars.gov.et
What This Immunome Sale Means a Day Before a Big FDA Milestone - The Motley Fool
Analysts Are Bullish on These Healthcare Stocks: Immunome (IMNM), COMPASS Pathways (CMPS) - The Globe and Mail
Immunome Stock Up 32% in a Month: Here's What You Should Know - The Globe and Mail
Why Immunome (IMNM) Is Up 11.7% After FDA Accepts Varegacestat NDA For Desmoid Tumors - Sahm
symbol__ Stock Quote Price and Forecast - CNN
Form 4 Immunome Inc For: 9 July - Investing.com India
Form 4 Immunome Inc For: 9 July By Investing.com - Investing.com South Africa
Immunome CBO Horn Kinney sells $27,300 in stock By Investing.com - Investing.com South Africa
Immunome CBO Horn Kinney sells $27,300 in stock - Investing.com
Truist Financial Maintains Immunome(IMNM.US) With Buy Rating - Moomoo
Immunome Inc. (IMNM) CBO exercises options and sells 1,092 shares - Stock Titan
H.C. Wainwright reiterates Immunome stock rating on FDA filing By Investing.com - Investing.com India
H.C. Wainwright reiterates Immunome stock rating on FDA filing - Investing.com
Barclays Maintains Immunome(IMNM.US) With Buy Rating, Maintains Target Price $36 - Moomoo
Immunome Clears Key Regulatory Milestone as Lead Drug Goes Under FDA Review - Benzinga
Immunome secures FDA review for cancer drug varegacestat - grafa.com
Immunome granted FDA review for tumor candidate (IMNM:NASDAQ) - Seeking Alpha
FDA accepts Immunome NDA for desmoid tumor treatment varegacestat - Investing.com
FDA accepts Immunome NDA for desmoid tumor treatment varegacestat By Investing.com - Investing.com South Africa
2.44%
0.02%
大文字化:
|
ボリューム (24 時間):